Chinese companies Maxvax Biotechnology and Beijing Luzhu Biotechnology are raising funds to move their respective research and development programs for recombinant herpes zoster (shingles) vaccine candidates and new adjuvant products.
https://www.pharmalive.com/wp-content/uploads/2021/07/Money-on-the-Move-June-30-–-July-6-BioSpace-2021.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-07-22 11:21:172022-07-22 11:23:15Chinese Biotechs Garner Millions for Shingles Vaccine Candidate to Rival GSK's Shingrix
